GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NuCana plc
The shares of NuCana, an oncology biotech, reflect the potential of its chemotherapy platform. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - General oncology therapy
NuCana is a Scottish oncology company developing a new generation of chemotherapy drugs that penetrate cancer cells more effectively. We've categorized it as a "General Oncology" company. The chart below shows how the market views innovative approaches to chemotherapy.
Broad Market Index - GURU.Markets
NuCana is a British biotech company developing a new generation of chemotherapy drugs that penetrate cancer cells more effectively. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how NuCana compares to it.
Change in the price of a company, segment, and market as a whole per day
NCNA - Daily change in the company's share price NuCana plc
For NuCana plc, an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs. The oncology sector is known for its high volatility. The chart below shows average daily fluctuations in this industry, allowing one to assess how NCNA's performance aligns with overall trends.
Daily change in the price of a broad market stock, index - GURU.Markets
NuCana is a Scottish biotech company developing cancer treatments. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NuCana plc
NuCana plc's year-end performance is a story about the development of its new class of chemotherapy drugs, ProTide. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which promises more effective drug delivery to cancer cells, could be a breakthrough in oncology.
Annual dynamics of market capitalization of the market segment - General oncology therapy
NuCana plc is a clinical-stage biotech developing a new generation of chemotherapy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NuCana, a biopharmaceutical company developing a new generation of chemotherapy, aims to improve the effectiveness of cancer treatments and reduce side effects. Comparing its year-over-year market capitalization dynamics with the market reveals how investors view the potential of its ProTide technology. It's a classic biotech story where clinical data is king.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NuCana plc
NuCana is a clinical-stage oncology company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its prodrugs, presented at conferences, is a key event, generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
NuCana is a biotech company developing a new generation of chemotherapeutic agents (prodrugs) designed to be more effective and less toxic. Its future depends on clinical success. The oncology sector's timeline reflects a general interest in innovation, allowing us to assess whether NuCana's technology can improve existing treatment standards.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
NuCana is a Scottish oncology company. Its US-traded shares follow news about clinical trials of its innovative chemotherapy delivery technology. The stock's dynamics are completely unrelated to overall market trends and reflect investors' faith in the company's scientific approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NuCana plc
NuCana, an oncology company developing improved versions of existing chemotherapy drugs, relies on clinical data. Its weekly stock price is reflecting research results demonstrating that its technology is truly superior to standard treatment.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
NuCana is developing a new generation of chemotherapy drugs with the goal of improving their effectiveness. The company's success depends entirely on the results of clinical trials. This chart shows how its weekly stock price fluctuates compared to the oncology sector average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NuCana is an oncology company developing a new generation of chemotherapy. Its future depends entirely on the success of clinical trials. The chart clearly demonstrates how its shares exist in a world of their own, independent of overall market trends.
Market capitalization of the company, segment and market as a whole
NCNA - Market capitalization of the company NuCana plc
NuCana's market capitalization chart reflects investors' valuation of its ProTide chemotherapy platform for improving cancer drugs. Its performance reflects the market's belief that its technology can make existing chemotherapies more effective and less toxic. Its low valuation is a response to previous clinical failures and hope for success in new programs.
NCNA - Share of the company's market capitalization NuCana plc within the market segment - General oncology therapy
NuCana is a British biopharmaceutical company developing next-generation chemotherapy. Its market share in the oncology sector is small, but it is based on its innovative ProTide technology. Its market cap reflects the valuation of its platform, which is designed to improve the efficacy and reduce toxicity of cancer treatments.
Market capitalization of the market segment - General oncology therapy
This chart shows the overall value of the entire oncology sector. For NuCana, with its innovative chemotherapy drug delivery technology, this line represents the future of cancer treatment. The rising chart reflects investors' belief that new technologies will make older, proven drugs more effective and less toxic.
Market capitalization of all companies included in a broad market index - GURU.Markets
NuCana is an oncology company developing a new generation of chemotherapy that is expected to be more effective and less toxic. Its market capitalization is the valuation of its "smart" chemotherapy. This represents the market share of the overall market for its attempts to improve on older treatments.
Book value capitalization of the company, segment and market as a whole
NCNA - Book value capitalization of the company NuCana plc
NuCana plc is an oncology company developing next-generation chemotherapy. Its book value represents its financial resources for conducting global clinical trials. It consists of cash that fuels its research and development. How has this capital changed? The chart below shows this story.
NCNA - Share of the company's book capitalization NuCana plc within the market segment - General oncology therapy
NuCana plc is an oncology company developing a new generation of chemotherapy. Its innovative ProTide technology requires a resource base: R&D centers for the creation and testing of new anticancer drugs. The chart shows the company's share of the physical R&D infrastructure in this biopharma segment.
Market segment balance sheet capitalization - General oncology therapy
NuCana is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. NuCana focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
NuCana's assets are not its factories, but its patented ProTide technology, which improves the effectiveness of chemotherapy drugs. Its book value reflects the capital invested in clinical trials of drug candidates created on this platform. The chart illustrates the scale of this British biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NuCana plc
NuCana is a Scottish oncology company developing improved versions of chemotherapy drugs. Its market value is derived from its ProTide technology, which promises to make treatment more effective and less toxic.
Market to book capitalization ratio in a market segment - General oncology therapy
NuCana is a Scottish biotech company developing next-generation chemotherapy. Its high valuation on this chart reflects investors' belief that its technology can make cancer treatment more effective and less toxic, the holy grail of oncology.
Market to book capitalization ratio for the market as a whole
NuCana plc is developing a new generation of chemotherapy drugs. The company's market capitalization reflects its hopes that its ProTide technology will significantly improve cancer treatment. This chart shows how highly the market can value scientific potential even without current sales, particularly in oncology.
Debts of the company, segment and market as a whole
NCNA - Company debts NuCana plc
NuCana, a Scottish biopharmaceutical company developing improved versions of chemotherapy drugs, is funding its extensive clinical trials with raised capital. This chart shows the enormous financial outlay required to prove the superiority of its technology over existing cancer treatments.
Market segment debts - General oncology therapy
NuCana is a Scottish clinical-stage biopharmaceutical company developing a new generation of chemotherapy drugs that it claims may be more effective and less toxic. This chart shows how the company is funding its expensive clinical trials to test this hypothesis and compete in the complex field of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NuCana plc
NuCana is a Scottish biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy. Clinical trials in oncology are among the most expensive processes in medicine. This chart shows how much the company relies on debt to finance its innovative, yet risky, research.
Market segment debt to market segment book capitalization - General oncology therapy
NuCana is a biopharmaceutical company developing next-generation chemotherapy drugs with the goal of improving their effectiveness. Oncology is a very expensive field. This chart shows how the company finances its clinical research, comparing its debt structure to the overall financial picture of the biotech sector.
Debt to book value of all companies in the market
NuCana plc is developing a new generation of chemotherapy drugs that are expected to be more effective and less toxic. Cancer research is a long and expensive process. How heavily does NuCana rely on debt? This chart of total market debt provides investors with context for assessing its financial strength and risks.
P/E of the company, segment and market as a whole
P/E - NuCana plc
NuCana is a British biopharmaceutical company developing a new generation of chemotherapeutic drugs designed to overcome drug resistance mechanisms. This chart shows how investors value its ProTide technology. The valuation is heavily dependent on clinical trial results.
P/E of the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs designed to overcome cancer cell resistance mechanisms. This chart illustrates the average valuation in the oncology research sector, where investors are betting on technologies that can improve the effectiveness of standard chemotherapy.
P/E of the market as a whole
NuCana plc is a clinical-stage biopharmaceutical company developing a new generation of chemotherapeutic drugs (ProTides) designed to overcome key mechanisms of cancer resistance. This chart reflects investors' overall risk appetite. It helps understand whether NCNA's valuation is based on faith in its innovative technology or whether it moves in line with overall biotech sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NuCana plc
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs designed to overcome cancer cell resistance mechanisms. This chart shows how much investors believe NuCana's technology can significantly improve cancer treatment outcomes, which shapes future revenue expectations.
%20P%2FE%20NuCana%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NuCana-plc&v=1772675782550 "Chart of the company's future (projected) P/E NuCana plc")
Future (projected) P/E of the market segment - General oncology therapy
NuCana is a biopharmaceutical company developing a new generation of chemotherapeutic agents (prodrugs) that are expected to be more effective and safe. The chart reflects future revenue expectations in the sector and helps understand how highly the market values the potential of NuCana's ProTide technology to improve cancer treatment.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772675782621 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs that are expected to be more effective and less toxic. This graph of overall risk appetite shows how willing investors are to fund companies seeking to improve existing cancer treatments rather than create entirely new ones.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772675782633 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NuCana plc
NuCana plc is a clinical-stage biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy and reduced toxicity. Financial indicators reflect R&D expenses. This chart shows investments in a technology that aims to improve one of the leading cancer treatments.
Profit of companies in the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing next-generation chemotherapeutic agents (prodrugs) designed to more effectively penetrate cancer cells and overcome resistance. This chart reflects overall profitability in the oncology sector, where improving existing treatments is a key focus alongside the development of new ones.
Overall market profit
NuCana plc is a Scottish biopharmaceutical company developing a new generation of chemotherapy. Its success depends entirely on the results of clinical trials. The need for more effective and less toxic cancer treatments is enormous and is not dependent on the state of the economy. The dynamics in this chart do not affect NuCana's scientific process or potential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NuCana plc
NuCana is an oncology company developing next-generation chemotherapy drugs designed to overcome drug resistance mechanisms. Future profits are entirely dependent on the clinical success of its ProTide technology. This chart reflects analyst expectations regarding its ability to improve existing cancer treatment standards.
%20profit%20of%20the%20company%20NuCana%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NuCana-plc&v=1772675782734 "Graph of future (projected) profit of the company NuCana plc")
Future (predicted) profit of companies in the market segment - General oncology therapy
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs that are expected to be more effective and less toxic than existing ones. Its ProTide technology aims to overcome drug resistance. This chart shows revenue projections for the oncology sector, providing context for evaluating NuCana's innovations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772675782752 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapeutic drugs. Its prospects depend on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for financing long-term biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772675782777 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NuCana plc
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs. Being in the clinical stage, it has no sales revenue. This chart reflects investors' faith in its ProTide technology, which is designed to make chemotherapy more effective and less toxic.
P/S market segment - General oncology therapy
NuCana is a clinical-stage biopharmaceutical company developing a new generation of chemotherapy drugs using its ProTide technology. This technology is designed to improve the effectiveness of cancer treatments and reduce side effects. This chart reflects the average revenue estimate for the sector, which helps assess the potential of NuCana's innovative platform.
P/S of the market as a whole
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy and safety. This chart highlights that the valuation of such companies is based on expectations of clinical trial results, not current sales, making them high-risk but potentially highly profitable.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NuCana plc
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs designed to be more effective and less toxic. Its revenue valuation is critical, reflecting investors' faith in its ProTide technology and the potential of its drug candidates to improve treatment outcomes for various types of cancer.
%20P%2FS%20NuCana%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NuCana-plc&v=1772675782883 "The graph of the company's future (projected) P/S NuCana plc")
Future (projected) P/S of the market segment - General oncology therapy
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs that more effectively penetrate cancer cells. This chart compares the company's estimated future sales with expectations for the oncology sector. It shows how investors view the potential of its ProTide technology to improve existing cancer treatment standards.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772675782924 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
NuCana is developing a new generation of chemotherapeutic agents (prodrugs) designed to overcome cancer cell resistance mechanisms. The company's future depends on the clinical success of its ProTide technology. This market outlook chart reflects investor confidence in innovation, even in a traditional field like chemotherapy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772675782993 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NuCana plc
This chart shows the financial performance of NuCana plc, a clinical-stage biopharmaceutical company developing a new generation of chemotherapeutic drugs. There is no commercial sales revenue, and the financial indicators reflect expenses related to clinical trials and raising capital for further development.
Sales of companies in the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy. Currently in the clinical stage, it does not yet have revenue. Its future revenue depends on the success of its ProTide technology in treating various types of cancer, demonstrating its innovative approach.
Overall market sales
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy. Its success depends on the results of clinical trials. This overall economic activity chart is irrelevant for a company whose mission is to improve the standard of cancer treatment, where innovation is constantly needed.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NuCana plc
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapeutic agents (prodrugs) that are more effectively delivered to cancer cells. Future revenue depends on the success of clinical trials. This chart shows analysts' forecasts for the commercial potential of its ProTide technology in the treatment of various cancer types.
%20sales%20of%20the%20company%20NuCana%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NuCana-plc&v=1772675783271 "Schedule of future (projected) sales of the company NuCana plc")
Future (projected) sales of companies in the market segment - General oncology therapy
NuCana plc is developing a new generation of chemotherapy drugs with improved safety and efficacy profiles. This chart shows revenue forecasts for the entire oncology market. Is growth expected due to innovations in drug delivery to tumor cells? This reflects the overall potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772675783349 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs. Its success depends on the results of clinical trials and their superiority over existing treatments. The overall economic trends reflected in this chart do not impact cancer patients' need for more effective and safer drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772675783401 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NuCana plc
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs that are expected to be more effective and less toxic. This chart reflects its financial performance at the clinical trial stage. Profitability depends on whether its ProTide drugs prove superior to existing cancer treatment standards.
Market segment marginality - General oncology therapy
NuCana plc is a clinical-stage biopharmaceutical company developing a new generation of chemotherapeutic agents designed to overcome the limitations of existing cancer treatments. This chart reflects its financial position, with profitability as a goal dependent on the success of its innovative technology in clinical trials.
Market marginality as a whole
NuCana plc is an oncology company developing a new generation of chemotherapy drugs. Its goal is to improve treatment efficacy and reduce side effects. This overall return chart reflects the investment climate. In a healthy economy, investors are more willing to fund biotech companies that strive to improve existing treatment standards.
Employees in the company, segment and market as a whole
Number of employees in the company NuCana plc
NuCana is a clinical-stage biotechnology company developing next-generation chemotherapy drugs. Its staff consists of scientists and clinical development specialists. This graphic shows the team working to advance their candidates through complex and expensive clinical trials for the treatment of various cancers.
Share of the company's employees NuCana plc within the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs with improved efficacy. Its core business is conducting expensive and lengthy clinical trials. This chart shows the company's market share, reflecting the scale of its clinical programs and the size of its scientific and medical teams.
Number of employees in the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs using ProTide technology. This technology enables more efficient delivery of active substances to cancer cells. The chart reflects activity in the general oncology sector. NuCana's approach has the potential to improve the efficacy and safety of existing treatments.
Number of employees in the market as a whole
NuCana is a biopharmaceutical company developing a new generation of chemotherapy drugs. Its growth depends on the results of clinical trials. This chart illustrates general economic cycles, placing NuCana in the context of the scientific world, where employment is driven by long-term investments in research and development to fight cancer.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NuCana plc (NCNA)
NuCana is a biotech company developing a new generation of chemotherapy using its ProTide platform. Their asset is their technology. This chart shows the market premium placed on their R&D. It reflects the market value per scientist, which is a direct measure of the intellectual capital and potential of their ProTide platform.
%20of%20the%20company%20NuCana%20plc%20(NCNA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NuCana-plc-NCNA&v=1772675783723 "Chart of market capitalization per employee (in thousands of dollars) of the company NuCana plc (NCNA)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
NuCana (NCNA) is an oncology company using its ProTide technology to improve existing chemotherapy drugs. This chart reflects the value of the improvement platform. A high value per employee may indicate that their technology can make existing drugs more effective and less toxic, which is a very valuable proposition.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772675783829 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
NuCana is a biotech company developing a new generation of chemotherapy drugs with improved efficacy. Its valuation is based on the potential of its ProTide technology. The chart shows a high valuation per employee, as the market believes its approach can significantly improve treatment outcomes for many types of cancer.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772675783892 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NuCana plc (NCNA)
NuCana is a clinical-stage biotech company developing a new generation of chemotherapy. Like most R&D biotech companies, this chart shows the company's per-employee loss. It reflects how much the company invests in each scientist to prove the superiority of its drug candidates over existing treatment standards.
%20Chart%20NuCana%20plc%20(NCNA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NuCana-plc-NCNA&v=1772675783902 "Company Profit Per Employee (in thousands of dollars) Chart NuCana plc (NCNA)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
NuCana plc is a biopharmaceutical company developing a new generation of chemotherapy drugs. Their ProTide technology aims to improve the effectiveness of cancer treatment. The graph shows the financial return generated by the team working on this innovative platform, allowing one to evaluate its potential compared to traditional treatment methods.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772675783926 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
NuCana is a Scottish biotech company developing a new generation of chemotherapy (ProTides), which is expected to be more effective and less toxic. It's an R&D company at the forefront of science. This chart, showing average market profitability, illustrates how the biotech model, with its small workforce and high stakes, differs from the rest of the economy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772675783930 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NuCana plc (NCNA)
NuCana plc is a clinical-stage oncology company. Zero revenue per employee is the norm at this stage. The graph symbolizes the potential of biotech: if their chemotherapy technology, ProTide, is successful, this metric could skyrocket, demonstrating the effectiveness of their scientific approach.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NuCana-plc-NCNA&v=1772675783932 "Sales chart per company employee NuCana plc (NCNA)")
Sales per employee in the market segment - General oncology therapy
NuCana plc is a clinical-stage biotech developing next-generation chemotherapy (prodrugs) for cancer treatment. They have no commercial revenue. This chart, showing the average industry revenue, serves as a barometer of NCNA's R&D staff burn rate compared to other oncology biotechs.
Sales per employee for the market as a whole
NuCana is a biotech company working to improve chemotherapy. They are developing "pro-drugs" (ProTides) that more effectively attack cancer cells. This chart reflects their R&D status: the company is in clinical trials and has no commercial revenue yet.
Short shares by company, segment and market as a whole
Shares shorted by company NuCana plc (NCNA)
NuCana (NCNA) is an oncology company developing next-generation chemotherapy that promises to be more effective and less toxic. This chart shows the number of short positions. These bears are betting that these drugs will not show significant advantages over existing, low-cost generic chemotherapy options in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NuCana-plc-NCNA&v=1772675784007 "Short Shares Chart for the Company NuCana plc (NCNA)")
Shares shorted by market segment - General oncology therapy
NuCana (NCNA) is an oncology company developing a new generation of chemotherapy (ProTides), which is expected to be more effective and less toxic. This chart aggregates short positions across the entire oncology biotech sector. It reflects general investor skepticism regarding the risks of clinical trials of new chemotherapy platforms.
Shares shorted by the overall market
NuCana (NCNA) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing NCNA won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NuCana plc (NCNA)
NuCana (NCNA) is a Scottish biotech company developing a new generation of chemotherapy (ProTides) to overcome resistance to cancer treatments. This indicator measures the rate of price change. It helps identify when enthusiasm (above 70) for the technology or disappointment (below 30) in the data peaks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NuCana-plc-NCNA&v=1772675784169 "RSI 14 indicator chart for the company's stock NuCana plc (NCNA)")
RSI 14 Market Segment - General oncology therapy
NuCana plc is a British oncology company developing a new generation of chemotherapy (ProTides), which it believes is more effective and less toxic than existing standards. This chart shows the overall sentiment in the oncology biotech sector. It helps us understand whether NCANA's momentum is driven by its clinical data or is a general "wave" across the industry.
RSI 14 for the overall market
NuCana (NCNA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NCNA (NuCana plc)
NuCana is a Scottish biopharmaceutical company. It uses its ProTide technology to "enhance" existing chemotherapy drugs, making them more effective against cancer. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of this R&D platform in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NCNA-NuCana-plc&v=1772675784239 "A chart showing analyst consensus forecasts for the expected stock price. NCNA (NuCana plc)")
The difference between the consensus estimate and the actual stock price NCNA (NuCana plc)
NuCana is a biotech company trying to "hack" chemotherapy. Their R&D platform (ProTide) is designed to create more effective and less toxic cancer drugs. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this R&D strategy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NCNA-NuCana-plc&v=1772675784286 "A chart showing the difference between the consensus forecast and the actual stock price. NCNA (NuCana plc)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
NuCana (NCNA) is a biotech company developing an "improved" chemotherapy (ProTide technology) that is expected to be more effective and safer than older drugs. This chart shows the overall expectations of oncology analysts. It reflects whether experts believe the company can "improve" chemotherapy.
Analysts' consensus forecast for the overall market share price
NuCana is a Scottish biotech company developing prodrugs (ProTides) designed to improve the effectiveness of chemotherapy. This chart reflects the overall market "risk appetite." For NuCana, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NuCana plc
NuCana is a Scottish biotech R&D company trying to crack chemotherapy. Their signature drug (ProTide) is a technology that repackages old, well-known chemotherapy drugs into a new form to trick cancer cells and make the treatment more effective. This chart is a clear indicator of faith in their R&D. It reflects their (slow) progress in clinical trials and their (high) risks.
AKIMA Market Segment Index - General oncology therapy
NuCana (NCNA) is an oncology company that uses Trojan horse technology (ProTide). They take known but ineffective chemotherapy drugs and disguise them so they can trick cancer cells, penetrate them, and bypass resistance mechanisms. This chart shows the average index for the segment, helping to assess how this clever R&D strategy compares to the average.
The AKIM Index for the overall market
NuCana is a biopharmaceutical company using ProTide technology to create safer and more effective chemotherapy drugs. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this strategy of improving proven molecules compares to overall economic trends.
